Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Hepatocellular 18Colorectal Neoplasms 17Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 9Advanced Solid Tumor 9Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Esophageal Neoplasms 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Injections 6pembrolizumab 5toripalimab 3tislelizumab 3senaparib 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor × tislelizumab × 1 year × Clear all
NCT06487858 2026-05-11

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

BeOne Medicines

Phase 1 Terminated
42 enrolled
Other solid neoplasm

Solid Tumor

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Sichuan University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡